Rute M Cerqueira1, Manuel R Correia2, Hélder Vilar2, M Conceição Manso3,4. 1. Gastroenterology, Centro Hospitalar entre Douro e Vouga, Santa Maria Feira, Portugal. rute.cerqueira@chedv.min-saude.pt. 2. Gastroenterology, Centro Hospitalar entre Douro e Vouga, Santa Maria Feira, Portugal. 3. Biostatistics, Faculty of Health Sciences, FP-ENAS, University Fernando Pessoa, Porto, Portugal. 4. LAQV@REQUIMTE-UP, Porto, Portugal.
Abstract
AIMS AND METHODS: Our aim was to assess, in obese patients undergoing Roux-en Y gastric bypass surgery, the quadruple concomitant HP eradication rates at first line treatment as proposed by the Maastricht IV consensus in areas of high clarithromycin resistance rates-proton pump inhibitor bid, clarithromycin 500 mg bid, amoxicillin 1000 mg bid, and metronidazole 500 mg bid. This is a single center prospective study over a 3-year period. Endoscopy and HP assessment (by histology or C13 urea breath) were performed at baseline, and post treatment HP status was assessed by C13 urea breath test 4-6 weeks after the end of therapy. RESULTS: The study cohort consisted of 600 adult obese HP positive patients [19 % male/81 % female, age 40.7 (±10.4) years] consecutively scheduled for HP concomitant therapy. HP was eradicated in 416 patients [69.3 % (95% CI 65.5-72.9 %)] and the eradication was independent of gender, age, endoscopic diagnosis, and smoking status (p > 0.05). CONCLUSIONS: Two weeks quadruple concomitant therapy did not achieve Maastricht recommended first line acceptable HP eradication rates (at least 80 %) in obese Portuguese patients undergoing GB.
AIMS AND METHODS: Our aim was to assess, in obesepatients undergoing Roux-en Y gastric bypass surgery, the quadruple concomitant HP eradication rates at first line treatment as proposed by the Maastricht IV consensus in areas of high clarithromycin resistance rates-proton pump inhibitor bid, clarithromycin 500 mg bid, amoxicillin 1000 mg bid, and metronidazole 500 mg bid. This is a single center prospective study over a 3-year period. Endoscopy and HP assessment (by histology or C13 urea breath) were performed at baseline, and post treatment HP status was assessed by C13 urea breath test 4-6 weeks after the end of therapy. RESULTS: The study cohort consisted of 600 adult obese HP positivepatients [19 % male/81 % female, age 40.7 (±10.4) years] consecutively scheduled for HP concomitant therapy. HP was eradicated in 416 patients [69.3 % (95% CI 65.5-72.9 %)] and the eradication was independent of gender, age, endoscopic diagnosis, and smoking status (p > 0.05). CONCLUSIONS: Two weeks quadruple concomitant therapy did not achieve Maastricht recommended first line acceptable HP eradication rates (at least 80 %) in obese Portuguese patients undergoing GB.
Authors: Peter Malfertheiner; Francis Megraud; Colm A O'Morain; John Atherton; Anthony T R Axon; Franco Bazzoli; Gian Franco Gensini; Javier P Gisbert; David Y Graham; Theodore Rokkas; Emad M El-Omar; Ernst J Kuipers Journal: Gut Date: 2012-05 Impact factor: 23.059
Authors: P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers Journal: Gut Date: 2006-12-14 Impact factor: 23.059
Authors: Rute M Cerqueira; Manuel R Correia; Carolina D Fernandes; Hélder Vilar; M Conceição Manso Journal: Obes Surg Date: 2013-02 Impact factor: 4.129
Authors: Rute Maria Cerqueira; M Conceição Manso; Manuel R Correia; Carolina D Fernandes; Hélder Vilar; Mário Nora; Paulo Martins Journal: Obes Surg Date: 2011-09 Impact factor: 4.129
Authors: H Yamamoto; Y Sekine; Y Sato; T Higashizawa; T Miyata; S Iino; K Ido; K Sugano Journal: Gastrointest Endosc Date: 2001-02 Impact factor: 9.427